ATS: Inhaled Corticosteroid Does Not Affect Childhood Growth Adversely
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




ATS: Inhaled Corticosteroid Does Not Affect Childhood Growth Adversely

By Charlene Laino

ORLANDO, FL -- May 25, 2004 -- While budesonide can slow the growth rate of children in the first year of treatment, the inhaled corticosteroid does not appear to have an adverse effect on height over the long term, according to a new analysis of data from the inhaled Steroid Treatment As Regular Therapy in early asthma (START) trial.

"For children aged 6 years to 11 years, budesonide has a small effect on height that is marked in the beginning and gone after 3 years," said study author Soren Petersen, MD, PhD, professor of pediatric respiratory medicine at the University of South Denmark in Odense, Denmark.

"In the long run, adult height does not appear to be adversely affected by 5 years of treatment with inhaled budesonide," said Dr. Petersen, who presented the findings on May 23rd at the American Thoracic Society, 100th International Conference.

The 5-year, 24-nation study consisted of 2 phases: (1) a 3-year double-blind randomized phase in which patients received budesonide or placebo once daily; followed by (2) a 2-year, open-label phase in which all patients received budesonide. In both phases, the children continued to take their usual asthma medication.

Children younger than 11 years at study entry were prescribed 200 mcg of budesonide during both phases, while older children received 400 mcg.

The researchers found that after 3 years of treatment,, the increase in height was an average of 1.29 cm less in the treated group than in the placebo arm. The first year of treatment accounted for most of the difference in growth (P < .0001), Dr. Petersen said.

The height of children aged 5 who were treated for 5 years with budesonide was not significantly different than that of steroid-naive patients of similar age at study entry, Dr. Petersen reported.

"This study is the largest and longest of any study looking at the effect of corticosteroids on growth in children," he said, "and thus has high power, enabling detection of small differences that would have been missed in smaller studies."

While the researchers studied budesonide, Dr. Petersen said he expects that the results apply to other corticosteroids as well.

[Presentation title: "Growth and Adult Height in Children Treated with Budesonide for 5 years in the START study." Abstract #A37 Poster #J98]


E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities